Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC01 and 10-1074 in HIV-infected individuals undergoing treatment interruptions
NCT03831945Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2019
- Primary completion
- Dec 2020
- Modality
- Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing VRC01 + 10-1074 with Placebo (2 arms). Primary endpoint: Days From Start of the Second Treatment Interruption Until the Subject Meets Criteria to Restart ART at 16 weeks. Started Apr 2019; status: terminated.
02
Drugs
VRC01zinlirvimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03831945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03831945.